DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20183505

Subcutaneous Anti-D versus intravenous methylprednisolone for the treatment of immune thrombocytopenic purpura

Olia Sharmeen, Mohammod Hasanur Rashid, Md Abdur Rouf, Afiqul Islam

Abstract


Background: Established treatment option for immune thrombocytopenic purpura (ITP) are intravenous immunoglobulin (IVIg), anti-D immunoglobulin’ and high dose intravenous methyl prednisolone (HIVMP). The present study was undertaken to compare the efficacy of subcutaneous bolus anti-D over HIVMP in the treatment of ITP.

Methods: A randomized clinical trial was conducted on a total 20 children with ITP, presented with extensive bleeding manifestation and platelet count <20 × 109/L;10 children received single dose subcutaneous anti-D (75 microgram/kg) and 10 children received HIVMP (30 mg/kg/dose) for 3 consecutive days. Patients were monitored for response to treatment and adverse events, platelet count and hemoglobin label were done in all patients at 24-hour, 48-hour, 72 hour, 1st week, 2nd week, 1st month, 2nd month and 3rd month after treatment to observe the change. Response rate define as a platelet count over 20 × 109/L within 72 hours of treatment. All the data were analyzed with the help of SPSS software version 16.0.

Results: By 24 hours of treatment 40% patient of anti-D and 10% patients of HIVMP group had platelet count >20 x109/L, by 72 hours 90% patients of both group achieved complete response (P =1.750). In HIVMP group the rate of remission gradually decreasing but in anti-D group it was persistently remain high. In anti-D group hemoglobin concentration decreased in 80% cases (P=0.023) but rate of decrease was not significant. New hemorrhage or significant extension of hemorrhage did not observe in any group.

Conclusions: A single dose of subcutaneous anti-D raised platelet count in children with ITP more rapidly and effectively than HIVMP (30 mg/kg/dose) with an acceptable safety profile.


Keywords


Anti-D immunoglobulin, High dose intravenous methylprednisolone, Idiopathic thrombocytopenic purpura

Full Text:

PDF

References


Segal JB, Power NR. Prevalence of immune thrombocytopenica: analyses of administrative data. J Thrombosis Haemostasis. 2006;4:2377-83.

Proven D, Norfolk D, Bolton-Maggs PHB. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574-96.

Shahgholi E, Vosough P, Sotoudeh K, Arjomandi K, Ansari S, Salehi S, et al. Intravenous immunoglobin versus intravenous anti-d immune globin for the treatment of acute immune thrombocytopenic purpura. Indian J Pediatr. 2008;137:1888-92.

Meyer O, Kiesewetter H, Hermsen M, Petriedes P, Rose N, Seibt H, et al. Replacement of intravenous administration of Anti-D by subcutaneous administrations in patients with autoimmune thrombocytopenia. Pediatric Blood Cancer. 2006;47:721-2.

Trebo MM, Frey E, Gadner H, Minkov M. Subcutaneous anti-D application is a safe treatment option of immune thrombocytopenia in children. Ann Hematol. 2010;89:415-8.

Scaradavou A, Woo B, Woloski BM, Cunninghum-Rundles S, Ettinger LJ, Aledort LM, et al. Intravenous anti-d treatment of immune thrombocytopenic purpura: experienced in 272 patients. Blood. 1997;89:2689-700.

Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, et al. Single dose of Anti-D immune globulin at 75 microgram/kg is as effective as intravenous immune globulin at rapidly rising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006;148:489-94.

Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, et al. Randomized trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisolone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344:703-7.

Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, Toxicity, and mechanism of effect. Blood. 1991;77:1884-93.

Kjaersgaard M. Treatment of Idiopathic thrombocytopenic Purpura (ITP) with subcutaneously administered Anti-D. Clinical Trials Gov Identifier. 2009;34:1-4.

Krishnamurti L, Charan VD, Desai N, Pati H, Choudhry VP. Anti-D immunoglobulin in the treatment of Idiopathic Thrombocytopenic Purpura. Indian J Pediatr. 1994;61:179-82.